Robert E. Landry - 16 Mar 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Issuer symbol
REGN
Transactions as of
16 Mar 2022
Net transactions value
-$315,832
Form type
4
Filing time
18 Mar 2022, 16:08:49 UTC
Previous filing
14 Dec 2021
Next filing
23 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale $203,100 -300 -1% $677.00 28,960 16 Mar 2022 Direct F1
transaction REGN Common Stock Sale $56,938 -83 -0.29% $686.00 28,877 17 Mar 2022 Direct F1
transaction REGN Common Stock Options Exercise $139,401 +365 +1.3% $381.92 29,242 17 Mar 2022 Direct
transaction REGN Common Stock Tax liability $195,195 -286 -0.98% $682.50 28,956 17 Mar 2022 Direct
holding REGN Common Stock 229 16 Mar 2022 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -365 -1.9% $0.000000 19,200 17 Mar 2022 Common Stock 365 $381.92 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.